Spanish Red Biotech Pipeline

Merck KGaA

Xevinapant (IAP inhibitor)

Type: Biodrugs/ Drugs
Therapeutic area: Cancer
Indication: Unresected, cisplatin-eligible locally advanced squamous cell carcinoma of the head and neck (SCCHN)
Phase: 3Phase III in Spain, 2Phase II, 1Phase I